JPM vs NAC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
NAC exhibits a weak deterministic health profile with a Piotroski F-Score of 3/9, indicating deteriorating fundamental trends. While the fund has delivered strong 1-year (+17.9%) and 3-year (+33.7%) price appreciation, the current technical trend is heavily bearish (0/100). The investment case relies primarily on its 7.44% dividend yield and a sustainable payout ratio of 61.69%, though it currently trades at a slight premium to book value (P/B 1.07).
Compare Another Pair
Related Comparisons
JPM vs NAC: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Nuveen California Quality Municipal Income Fund (NAC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.